Thomas Powles, Michiel S. Van Der Heijden, Jens Bedke, BegoƱa P. Valderrama, Eiji Kikuchi, Matthew D. Galsky, Yohann Loriot, Gopa Iyer, Evan Y. Yu, Jeannie Hoffman-Censits, Nataliya Mar, Christof Vulsteke, Srikala S. Sridhar, Jose Pablo Maroto-Rey, Se Hoon Park, Blanca Homet Moreno, Jasmine Lichfield, Xuesong Yu, Heidi Wirtz, Shilpa Gupta. "Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4507